The FDA recently approved generic versions of the attention deficit hyperactivity disorder (ADHD) drug Intuniv and the birth control pill Seasonique.
TWi Pharmaceuticals Inc. June 3 announced that the Food and Drug Administration has approved its generic version of Shire’s Intuniv (guanfacine hydrochloride) extended-release tablet.
The company said its marketing partner, Par Pharmaceuticals Inc., will launch the product in the U.S. market immediately.
The total annual sales of guanfacine HCl ER tablets in the U.S. were approximately $751 million for the 12 months ending December 2014, according to the consulting firm IMS Health.
Mylan Drugs.
In separate June 2 press ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.